Glomerulonephritis can affect the normal functioning of the kidneys, with consequences ranging from subtle, easily dismissed ...

In this presentation I will review evidence that immune complexes are responsible for the development of glomerulonephritis in systemic lupus erythematosus (SLE), and analyze the variables ...

and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). In the trial, study participants aged 12 years and older with C3G or primary IC-MPGN were randomly assigned to ...

The indications are C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). A filing accepted under the regulatory body’s Priority Review pathway ...

and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The FDA’s Prescription Drug User Fee Act (PDUFA) target action date is set for 28 July 2025. The application is ...

CFI deficiency can also manifest in renal conditions such as atypical hemolytic uremic syndrome, complement 3 glomerulopathy, or immune-complex membranoproliferative glomerulonephritis.

Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli ...